Physician profile
John Meyer
NPI 1801828041
$1,002.64
in general payments reported to CMS, 2019-2025
27 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $105 · 2021: $189 · 2022: $45.52 · 2023: $155 · 2024: $175 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.63 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $102.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $79.32 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.01 | 2020-2025 | Xifaxan |
| Antares Pharma, INC. | $59.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $52.95 | 2024-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $50.22 | 2023-2024 | |
| Lilly USA, LLC | $46.07 | 2019-2025 | Kisunla |
| Tolmar, INC. | $44.80 | 2024-2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $34.57 | 2023 | Quviviq |
| Averitas Pharma INC. | $29.50 | 2024 | Qutenza |
| Glaxosmithkline, LLC. | $29.38 | 2022-2023 | Trelegy Ellipta |
| Amgen INC. | $27.85 | 2019-2025 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $27.37 | 2019-2021 | |
| Abbott Laboratories | $23.42 | 2024 | Freestyle Libre 3 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $22.23 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.46 | 2025 | Caplyta |
| Allergan, INC. | $19.95 | 2020 | |
| Eisai INC. | $19.87 | 2020 | |
| Amarin Pharma, INC. | $18.85 | 2019 | |
| Philips North America LLC | $18.30 | 2023 | |
| Abbvie INC. | $15.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.27 | 2019 | |
| Therapeuticsmd, INC. | $13.17 | 2019 | |
| Aytu Biopharma, INC. | $13.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.